Brought to you by 
CANbridge pays $30mm up front for rights to Puma's Nerlynx; Agreement Terminated
26 Feb 2021
Executive Summary
Puma Biotechnology Inc. granted CANbridge Life Sciences Ltd. exclusive rights to develop and sell its breast cancer therapy Nerlynx (nerlatinib) in mainland China, Taiwan, Hong Kong, and Macau.
Deal Industry
- Biotechnology
- Pharmaceuticals
-
Pharmaceuticals
- Specialty Pharmaceuticals
Deal Status
- Terminated
Deal Type
-
Alliance
- Includes Royalty or Profit Split Information
- Intra-Biotech Deal
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
CANbridge pays $30mm up front for rights to Puma's Nerlynx; Agreement Terminated
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice